Category Archives: Yaz/Yasmin and Ocella

Subscribe to Yaz/Yasmin and Ocella RSS Feed

Bayer Faces Possible Embarrassment in Yaz and Yasmin Litigation

Posted in Defective Drugs, Yaz/Yasmin and Ocella

Bayer released a series of Saturday-morning-style cartoons for sales representative training purposes, which they seemingly hoped would motivate their sales reps to continue marketing their birth control drugs, including Yaz. One particular cartoon is entitled “IndiYaz A Jones and the Temple of Estradiol.” Estradiol is a hormone that is contained in the Yaz contraceptive, which… Continue Reading

Bayer Yaz and Yasmin Cases May Settle Within a Year

Posted in Defective Drugs, Yaz/Yasmin and Ocella

On July 11, 2012, The Madison Record reported that the special master appointed to oversee settlement negotiations for the federal MDL case, Stephen Saltzburg, estimates that negotiations could be concluded within a year. To date, it is reported that, almost 2,000 lawsuits have settled. As we previously advised, Bayer reports that it has set aside… Continue Reading

Bayer Yaz and Yasmin Settlements Increase to Over $400 Million

Posted in Defective Drugs, Yaz/Yasmin and Ocella

According to a recent Bloomberg article, Bayer reports that the settlements in the Yaz and Yasmin lawsuits have reached $402.6 million. As we previously reported, Bayer’s defense counsel is currently conducting and scheduling meetings with law firms nationwide to discuss possible settlement of cases. To date, almost 2,000 cases have settled. As we also previously… Continue Reading

FDA Mandates Changes to Label Warnings on Bayer Yaz

Posted in Defective Drugs, Yaz/Yasmin and Ocella

As previously reported, in December 2011, the Federal Drug and Administration (FDA) ruled that the label warning on Bayer Yaz and Yasmin regarding the increased risk of blood clots was inadequate. The decision followed a nine-hour hearing during which the FDA’s Advisory Committee listened to testimony and, according to the FDA website, “discuss[ed] the benefits… Continue Reading

Recent Study Links and Yasmin to Yaz Stroke and Heart Attack

Posted in Defective Drugs, Yaz/Yasmin and Ocella

In June 2012, a study, published in the New England Journal of Medicine, reported that that birth control products containing combined estrogen-progestin, such as Yaz or Yasmin, may double a woman’s risk of stroke and heart attack compared to other hormonal contraceptives. The study, based on data compiled over 15 years from more than 1.5… Continue Reading

Bayer Continues to Settle in the Yaz Lawsuit

Posted in Defective Drugs, Yaz/Yasmin and Ocella

Following the December 2011, ruling by the Federal Drug and Administration (FDA) that the label warnings on Yaz and Yasmin failed to adequately warn against the increased risk of blood clots, Bayer began contacting Plaintiffs across the country to settle their Yaz lawsuit. In April 2012, a Bloomberg article reported that Bayer had already settled… Continue Reading

Judge Asked To Consider Possible FDA Conflicts of Interest in YAZ Litigation

Posted in Defective Drugs, Yaz/Yasmin and Ocella

Recently, the Plaintiffs’ Steering Committee in the Yaz and Yasmin litigation opposed a motion to exclude the opinions of former Food and Drug Administration (FDA) commissioner, David Kessler, concerning possible conflicts of interest.  The Plaintiffs’ attorneys have asked Judge Herndon, who is overseeing the federal Yaz and Yasmin cases, to allow in evidence showing that… Continue Reading

Pennsylvania Follows Federal Judge and Sends Yaz cases to Mediation

Posted in Defective Drugs, Yaz/Yasmin and Ocella

On January 6, 2012, Judge Moss, who is overseeing the state Yaz cases in Philadelphia, followed in Judge Herndon’s footsteps and ordered the parties into mediation.  Like Judge Herndon, who is overseeing the federal Yaz cases, Judge Moss also appointed Professor Stephen Saltzburg of George Washington School of Law as Special Master, for the purposes… Continue Reading

First Federal Yaz Trial Sent to Mediation, NJ Trials Still On…For Now

Posted in Defective Drugs, Yaz/Yasmin and Ocella

The first federal Yaz trial is not moving forward as planned.  While the highly anticipated trial was originally scheduled to begin the second week of January 2012, Judge Herndon, who is overseeing the federal Yaz cases in the Southern District of Illinois, has now ordered both sides to mediation. On December 31, 2011, Judge Herndon… Continue Reading

Disagreements Continue Over Yaz Depositions

Posted in Defective Drugs, Yaz/Yasmin and Ocella

In November 2010, U.S. District Judge David Herndon, who is overseeing the federal Yaz lawsuits, ordered three executives from Bayer to fly to the United States for their depositions. Joachim Marr, Hartmut Blode and Ilka Schellschmidt, who work at Bayer’s headquarters in Germany, were selected to represent the company regarding the pre-clinical and clinical development processes.

Disagreements continue over Yaz depositions

Posted in Defective Drugs, Yaz/Yasmin and Ocella

In November 2010, U.S. District Judge David Herndon, who is overseeing the federal Yaz lawsuits, ordered three executives from Bayer to fly to the United States for their depositions. Joachim Marr, Hartmut Blode and Ilka Schellschmidt, who work at Bayer’s headquarters in Germany, were selected to represent the company regarding the pre-clinical and clinical development processes.

Update on YAZ® Case Management Conference

Posted in Defective Drugs, Yaz/Yasmin and Ocella

On December 16, 2010, counsel attended a Case Management Conference before Judge Martinotti in Bergen County Superior Court in Hackensack, New Jersey. It was agreed that counsel will continue to work together to depose, or question, the necessary witnesses from defendant Bayer Corporation, both domestically and internationally. Additionally, plaintiffs were granted authority to file a motion with the Court, seeking to compel the production of foreign personnel files from employees noticed for deposition, which the defendants argue is prohibited under German law. The motion is expected to be heard in early 2011.

YAZ® Lawsuit Update: Bellwether Trials in the Federal MDL Scheduled

Posted in Defective Drugs, Yaz/Yasmin and Ocella

A large number of YAZ® lawsuits were designated as Mass Tort or Multidistrict Litigation (MDL) cases over the past several months. Just recently, the three initial bellwether trials in the federal MDL were scheduled. Courts utilize a bellwether approach when there are a large numbers of plaintiffs proceeding on the same theory or claim, such as in the Yaz ® cases. Typically, a group of plaintiffs are chosen to represent all the plaintiffs with the same alleged ailment.

YAZ® Mass Tort Litigation Ordered To File Master Consolidated Complaint

Posted in Defective Drugs, Yaz/Yasmin and Ocella

The parties involved in the YAZ® Mass Tort litigation have been ordered file a Master Consolidated Complaint (“Master Complaint”). The Master Complaint will supplement the Complaints that have been filed in the individual cases, as well as serve as a reference for incoming plaintiffs. The Master Complaint will allege a variety of counts for Negligence, Fraud, and other causes of action.

YAZ® Mass Tort Litigation Update: Plaintiff Fact Sheet Wording Finalized

Posted in Defective Drugs, Yaz/Yasmin and Ocella

The parties involved in the Mass Tort litigation have agreed upon the wording of a form called the Plaintiff Fact Sheet. In pharmaceutical cases with Mass Tort or MDL designations, plaintiffs are required to submit a detailed Plaintiff Fact Sheet. The Plaintiff Fact Sheet requires the plaintiff to supply medical, liability and general background information within a specified time period, usually subject to periodic updating and revision.

YAZ®, Yasmin® and Ocella® – How to Determine Where a Case Should be Heard

Posted in Defective Drugs, Yaz/Yasmin and Ocella

YAZ®, Yasmin® and Ocella® are the subject of mass tort litigation treatment in the state courts of New Jersey and Pennsylvania, and MDL treatment in the federal courts, Southern District of Illinois. In many cases, based on the state of residence of the plaintiff, plaintiff’s counsel must make a determination as to which forum would be best for the plaintiff’s case. There are numerous factors that must be weighed in making this determination.

YAZ®, Yasmin® Mass Tort Litigation Update – Preservation of Documents

Posted in Defective Drugs, Yaz/Yasmin and Ocella

The parties involved in the Mass Tort litigation (surrounding the defective birth control products YAZ®, Yasmin® and Ocella®) have been ordered to confer and reach an agreement on all issues regarding the preservation of documents and data. The goal of preservation is to maintain the integrity of all documents, data and tangible things pursuant to R. 4:10 through R. 4:19.

New Jersey State Supreme Court Grants Mass Tort Designation to YAZ®, Yasmin® and Ocella® Cases

Posted in Defective Drugs, Yaz/Yasmin and Ocella

As we have discussed in previous posts, studies have shown that the ingredients contained in the birth control products YAZ®, Yasmin® and Ocella® have been linked to various forms of severe side-effects. Reportedly, these side-effects include: heart attack, stroke, deep vein thrombosis (also known as DVT or blood clots), internal organ damage (including gallbladder damage), myocardial infarction and pulmonary embolism.

Claims against the makers of YAZ®, Yasmin® and Ocella® Will Be Consolidated Before Judge Moss in Philadelphia County, Pennsylvania

Posted in Defective Drugs, Yaz/Yasmin and Ocella

A large number of claims against the makers of defective birth control products, YAZ®, Yasmin® and Ocella®, for injuries ranging from internal organ damage to deep vein thrombosis have been designated as Mass Tort cases in state court, to be consolidated for case management and discovery purposes before Judge Moss in Philadelphia County, Pennsylvania. In the Mass Tort, counsel recently argued before Judge Moss regarding discovery issues.

YAZ® Birth Control Linked to Serious Side Effects, Including Deep Vein Thrombosis

Posted in Defective Drugs, Yaz/Yasmin and Ocella

As we have discussed in previous posts, studies have shown that the ingredients contained in YAZ®, Yasmin® and Ocella® have been linked to various forms of severe side-effects. Reportedly, these side-effects include: heart attack, stroke, deep vein thrombosis (also known as DVT or blood clots), internal organ damage (including gallbladder damage), myocardial infarction and pulmonary embolism. Recently, a large number of YAZ® lawsuits have been designated as Mass Tort or Multidistrict Litigation (MDL) cases.